GlassScriptPhysician profile
Matthew Stiles Bowdish
NPI 1770767923
$120,461.27
in general payments reported to CMS, 2019-2025
51 companies · $2,188 in 2025
The $2,188 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $16K · 2021: $25K · 2022: $12K · 2023: $13K · 2024: $13K · 2025: $2,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,681 · Travel and Lodging: $2,165 · Consulting Fee: $575 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,875.00 |
| Food and Beverage | $6,680.83 |
| Travel and Lodging | $2,165.24 |
| Consulting Fee | $575.00 |
| Education | $120.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62,180.33 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $27,405.68 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,341.05 | 2019-2023 | Spiriva |
| Pharming Healthcare, INC. | $4,277.03 | 2019-2025 | Ruconest |
| Optinose US, INC. | $2,859.63 | 2019-2025 | |
| Alk-Abello, INC | $1,613.31 | 2019-2024 | Odactra, Grastek |
| Genzyme Corporation | $1,473.32 | 2019-2025 | |
| Biocryst Pharmaceuticals, INC. | $1,125.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $742.89 | 2019-2025 | Dupixent |
| Csl Behring | $675.70 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $668.41 | 2020-2025 | Cuvitru, Eohilia |
| Abbvie INC. | $613.87 | 2022-2023 | Rinvoq |
| Octapharma USA, INC. | $488.30 | 2019-2024 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $472.71 | 2019-2025 | |
| Genentech USA, INC. | $360.63 | 2019-2024 | Xolair |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $330.21 | 2022-2025 | Tezspire, Actimmune |
| Cochlear Americas | $310.00 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Grifols USA, LLC | $285.19 | 2019-2025 | Xembify |
| Kaleo, INC. | $278.44 | 2019-2023 | Auvi-Q |
| Genentech, INC. | $209.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $187.20 | 2019-2022 | |
| Pfizer INC. | $182.27 | 2020-2024 | |
| Bio Products Laboratory USA, INC. | $173.06 | 2022-2023 | Coagadex, Gammaplex |
| Shire North American Group INC | $163.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $106.94 | 2019 | |
| Horizon Therapeutics Plc | $76.71 | 2021-2023 | Actimmune |
| Circassia INC. | $76.57 | 2019 | |
| Mylan Specialty L.P. | $75.83 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $74.94 | 2024 | Inspire |
| Phadia US INC. | $57.19 | 2022-2024 | Immunocap |
| Leo Pharma INC. | $52.79 | 2022-2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $44.97 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $37.92 | 2021-2023 | Orladeyo |
| Arcutis Biotherapeutics, INC. | $36.93 | 2025 | Zoryve |
| Covis Pharma Gmbh | $36.52 | 2019-2022 | |
| Lilly USA, LLC | $33.19 | 2025 | Ebglyss, Taltz |
| Blueprint Medicines Corporation | $30.93 | 2021-2023 | Ayvakit |
| Boston Scientific Corporation | $30.81 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Ionis Pharmaceuticals, INC. | $29.78 | 2025 | Dawnzera |
| Incyte Corporation | $28.97 | 2024 | Opzelura |
| Aimmune Therapeutics, INC. | $27.76 | 2022 | |
| X4 Pharmaceuticals, INC. | $25.02 | 2024 | Xolremdi |
| Organon LLC | $24.79 | 2025 | Vtama |
| Kedrion Biopharma, INC. | $21.11 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Nestle Healthcare Nutrition INC. | $19.53 | 2023 | |
| Galderma Laboratories, L.P. | $19.43 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $17.16 | 2021 | |
| Advanced Respiratory, INC | $16.60 | 2019 | |
| Viatris Specialty LLC | $14.76 | 2025 | Yupelri |
| Greer Laboratories, INC. | $14.41 | 2019 | |
| Philips North America LLC | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bowdish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.